$285.98
1.62% day before yesterday
NYSE, Apr 11, 10:05 pm CET
ISIN
US0311621009
Symbol
AMGN
Sector
Industry

Amgen Stock price

$285.98
-32.91 10.32% 1M
-42.37 12.90% 6M
+25.34 9.72% YTD
+15.98 5.92% 1Y
+35.11 14.00% 3Y
+67.71 31.02% 5Y
+123.49 76.00% 10Y
NYSE, Closing price Fri, Apr 11 2025
+4.57 1.62%
ISIN
US0311621009
Symbol
AMGN
Sector
Industry

Key metrics

Market capitalization $153.63b
Enterprise Value $202.54b
P/E (TTM) P/E ratio 37.90
EV/FCF (TTM) EV/FCF 19.49
EV/Sales (TTM) EV/Sales 6.09
P/S ratio (TTM) P/S ratio 4.62
P/B ratio (TTM) P/B ratio 26.13
Dividend yield 3.15%
Last dividend (FY24) $9.00
Revenue growth (TTM) Revenue growth 18.64%
Revenue (TTM) Revenue $33.23b
EBIT (operating result TTM) EBIT $8.73b
Free Cash Flow (TTM) Free Cash Flow $10.39b
Cash position $11.97b
EPS (TTM) EPS $7.55
P/E forward 24.93
P/S forward 4.37
EV/Sales forward 5.76
Short interest 2.81%
Show more

Create a Free Account to create an Amgen alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Amgen Stock Analysis

Unlock Scores for Free

Analyst Opinions

31 Analysts have issued a Amgen forecast:

14x Buy
45%
14x Hold
45%
3x Sell
10%

Analyst Opinions

31 Analysts have issued a Amgen forecast:

Buy
45%
Hold
45%
Sell
10%

Financial data from Amgen

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
33,232 33,232
19% 19%
100%
- Direct Costs 11,282 11,282
33% 33%
34%
21,950 21,950
12% 12%
66%
- Selling and Administrative Expenses 1,693 1,693
32% 32%
5%
- Research and Development Expense 5,938 5,938
24% 24%
18%
14,319 14,319
17% 17%
43%
- Depreciation and Amortization 5,592 5,592
37% 37%
17%
EBIT (Operating Income) EBIT 8,727 8,727
6% 6%
26%
Net Profit 4,090 4,090
39% 39%
12%

In millions USD.

Don't miss a Thing! We will send you all news about Amgen directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Amgen Stock News

Negative
CNBC
one day ago
President Donald Trump's planned tariffs on pharmaceuticals imported into the U.S. could have wide-ranging consequences on the drug supply chain, manufacturers and American patients, some experts told CNBC.  The tariffs could disrupt the complex pharmaceutical supply chain, potentially driving up the prices of drugs in the U.S. and exacerbating shortages of critical medicine.
Neutral
PRNewsWire
one day ago
First Global Phase 3 Trial Showing Substantial Survival Advantage Over Chemotherapy, for Patients With Progression On or After Platinum-Based Chemotherapy THOUSAND OAKS, Calif. , April 11, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the global Phase 3 DeLLphi-304 clinical trial evaluating IMDELLTRA® (tarlatamab-dlle) as a treatment for patients with small cell lung cancer (SCL...
Positive
Barrons
2 days ago
The Company spend billions to produce 100% of its key medicines for Americans in the U.S.
More Amgen News

Company Profile

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, BLINCYTO, Corlanor, ENBREL, EPOGEN, IMLYGIC, KYPROLIS, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Head office United States
CEO Robert Bradway
Employees 28,000
Founded 1980
Website www.amgen.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today